Hideyuki Harada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hideyuki Harada has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
Tetsuo Nishimura
Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan
12 shared publications- Toshiaki Takahashi
Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
9 shared publications - Tateaki Naito
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
8 shared publications - Akira Ono
Shizuoka Cancer Center, Shizuoka, Japan
7 shared publications - Haruyasu Murakami
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
7 shared publications - Hirotsugu Kenmotsu
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
7 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226
Particle therapy for T3N0M0 non-small cell lung cancer: a Japanese nationwide prospective registry study
- 13 November 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226
Open AccessParticle therapy for T3N0M0 non-small cell lung cancer: a Japanese nationwide prospective registry study
- Open Access
- 18 June 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (9) , 1145-1151
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)
Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexate–based induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Bruton’s tyrosine kinase inhibitor. Tirabrutinib’s oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).
- 18 June 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (9) , 1145-1151
Open AccessA multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)
Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexate–based induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Bruton’s tyrosine kinase inhibitor. Tirabrutinib’s oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).
- Open Access
- 26 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111307
Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study
- 26 November 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 214, 111307
Open AccessLong-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 209-215
Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer
Objective: The aim of this study was to compare survival and the incidence of complications between stereotactic body radiotherapy/proton beam therapy (SBRT/PBT) and sublobar resection for vulnerable elderly patients with clinical stage IA non-small cell lung cancer (NSCLC). Methods: We included patients aged ≥75 years who underwent sublobar resection without mediastinal lymph node dissection or SBRT/PBT for solid predominant clinical stage IA non-small cell lung cancer measuring ≤3 cm in total size. Propensity score matching was used to reduce the selection bias. Complication and survival rates were compared between groups. Results: Of the 119 included patients, 86 received stereotactic body radiotherapy (62 received X-ray radiotherapy and 24 received proton beam therapy), while 33 received sublobar resection (11 received segmentectomy and 22 received wedge resection). The SBRT/PBT group included significantly older patients (median: 82 vs. 79 years) and larger tumors (median: 18 vs. 16 mm) than did the surgery group. After propensity score matching, 24 patients were analysed in each group. The incidence of ≥Grade 2 complications was not significantly different between the two groups (12.5% vs. 29.1%; OR = 0.35, 95% CI: 0.08–1.55; P = 0.286). Moreover, there were no significant differences in overall and recurrence-free survival rates (OS: HR = 0.68; 95% CI: 0.31–1.50; P= 0.343; RFS: HR = 0.69; 95% CI: 0.33–1.46; P = 0.336, respectively) and the cumulative incidence of recurrence (sHR = 0.87; 95% CI: 0.31–2.40; P = 0.781). Conclusions: For vulnerable elderly patients with NSCLC, SBRT/PBT may be comparable with sublobar resection in terms of patient survival and safety. Prospective randomized controlled trials are required to confirm these findings.
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 209-215
Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer
Objective: The aim of this study was to compare survival and the incidence of complications between stereotactic body radiotherapy/proton beam therapy (SBRT/PBT) and sublobar resection for vulnerable elderly patients with clinical stage IA non-small cell lung cancer (NSCLC). Methods: We included patients aged ≥75 years who underwent sublobar resection without mediastinal lymph node dissection or SBRT/PBT for solid predominant clinical stage IA non-small cell lung cancer measuring ≤3 cm in total size. Propensity score matching was used to reduce the selection bias. Complication and survival rates were compared between groups. Results: Of the 119 included patients, 86 received stereotactic body radiotherapy (62 received X-ray radiotherapy and 24 received proton beam therapy), while 33 received sublobar resection (11 received segmentectomy and 22 received wedge resection). The SBRT/PBT group included significantly older patients (median: 82 vs. 79 years) and larger tumors (median: 18 vs. 16 mm) than did the surgery group. After propensity score matching, 24 patients were analysed in each group. The incidence of ≥Grade 2 complications was not significantly different between the two groups (12.5% vs. 29.1%; OR = 0.35, 95% CI: 0.08–1.55; P = 0.286). Moreover, there were no significant differences in overall and recurrence-free survival rates (OS: HR = 0.68; 95% CI: 0.31–1.50; P= 0.343; RFS: HR = 0.69; 95% CI: 0.33–1.46; P = 0.336, respectively) and the cumulative incidence of recurrence (sHR = 0.87; 95% CI: 0.31–2.40; P = 0.781). Conclusions: For vulnerable elderly patients with NSCLC, SBRT/PBT may be comparable with sublobar resection in terms of patient survival and safety. Prospective randomized controlled trials are required to confirm these findings.
- Open Access
- 16 October 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (6) , 606-616
Inter-institutional variability in CT-to-mass-density conversion tables for helical tomotherapy: a national survey in Japan
This study evaluates current practices and challenges associated with computed tomography number-to-mass density (CT–MD) conversion tables in helical tomotherapy across Japan and explores directions for standardization and quality improvement amid the increasing adoption of adaptive radiotherapy (ART). A nationwide web-based survey was conducted across 34 institutions utilizing the Radixact system. Data were collected on CT acquisition protocols, calibration phantoms, density plugs, reconstruction algorithms, table registration timing and quality assurance (QA) frequency. Registered CT–MD tables were categorized by CT modality: Simulation CT (SimCT), ClearRT and CTrue. ClearRT tables were analyzed by phantom setup (full vs half), and CTrue tables by reconstruction method [filtered back projection (FPB) vs iterative reconstruction (IR)]. Inter-institutional variations in CT numbers and the number of data points were assessed. SimCT tables exhibited the widest variation in the number of data points (median = 10) and high-density CT numbers. ClearRT tables (median = 8) showed variations of up to 300 Hounsfield units (HU) in cortical bone; the half-phantom setup reduced inter-institutional variability. CTrue tables (median = 8) demonstrated high consistency, with negligible differences between IR and FPB. All plug CT numbers of CTrue remained within the tolerance defined by the American Association of Physicists in Medicine Task Group 148. However, CT numbers for air plugs varied by ~±30 HU, indicating inconsistent handling of air reference values. Additionally, 43% of institutions did not perform routine QA. Standardizing phantom geometry, air CT number handling and QA protocols—particularly using half-phantom calibration—may improve CT–MD table consistency and dose accuracy in ART.
- 16 October 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (6) , 606-616
Open AccessInter-institutional variability in CT-to-mass-density conversion tables for helical tomotherapy: a national survey in Japan
This study evaluates current practices and challenges associated with computed tomography number-to-mass density (CT–MD) conversion tables in helical tomotherapy across Japan and explores directions for standardization and quality improvement amid the increasing adoption of adaptive radiotherapy (ART). A nationwide web-based survey was conducted across 34 institutions utilizing the Radixact system. Data were collected on CT acquisition protocols, calibration phantoms, density plugs, reconstruction algorithms, table registration timing and quality assurance (QA) frequency. Registered CT–MD tables were categorized by CT modality: Simulation CT (SimCT), ClearRT and CTrue. ClearRT tables were analyzed by phantom setup (full vs half), and CTrue tables by reconstruction method [filtered back projection (FPB) vs iterative reconstruction (IR)]. Inter-institutional variations in CT numbers and the number of data points were assessed. SimCT tables exhibited the widest variation in the number of data points (median = 10) and high-density CT numbers. ClearRT tables (median = 8) showed variations of up to 300 Hounsfield units (HU) in cortical bone; the half-phantom setup reduced inter-institutional variability. CTrue tables (median = 8) demonstrated high consistency, with negligible differences between IR and FPB. All plug CT numbers of CTrue remained within the tolerance defined by the American Association of Physicists in Medicine Task Group 148. However, CT numbers for air plugs varied by ~±30 HU, indicating inconsistent handling of air reference values. Additionally, 43% of institutions did not perform routine QA. Standardizing phantom geometry, air CT number handling and QA protocols—particularly using half-phantom calibration—may improve CT–MD table consistency and dose accuracy in ART.
- Open Access
- 8 November 2024
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 41, 100849
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study
- 8 November 2024
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 41, 100849
Open AccessEfficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study
- Open Access
- 20 August 2024
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 65 (5) , 701-711
Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor
Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20–30 Gy (24%), 30–40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4–5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1–9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2–76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.
- 20 August 2024
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 65 (5) , 701-711
Open AccessMulti-institutional prospective observational study of radiotherapy for metastatic bone tumor
Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20–30 Gy (24%), 30–40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4–5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1–9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2–76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.
- 18 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110385
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry
- 18 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110385
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry
- Open Access
- 3 March 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1
Correction: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
- 3 March 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1
Open AccessCorrection: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
- Open Access
- 28 December 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-10
Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
Background: Linac-based fractionated stereotactic radiotherapy (fSRT) and stereotactic radiosurgery (SRS) are increasingly being used to manage patients with multiple metastases. This retrospective cohort study aimed to compare the outcomes after linac-based fSRT and SRS between three patient groups classified based on the number of brain metastases (BMs): 1 BM, 2–4 BM, 5–10 BM. Methods: The data of consecutive patients with 1–10 BMs treated with fSRT or SRS between July 2016 and June 2018 at a single institution were collected. Patients with previous whole-brain radiotherapy (WBRT), concurrent use of WBRT, or surgical resection were excluded from the analysis. A total of 176 patients were classified into three groups according to the number of BMs: 78, 67, and 31 patients in 1 BM, 2–4 BM, and 5–10 BM, respectively. The Kaplan–Meier method was used to estimate overall survival (OS) curves, and the cumulative incidence with competing risks was used to estimate local control (LC), distant intracranial failure (DIF), and radiation necrosis (RN). Results: Median OS was 19.8 months (95% confidence interval [CI] 10.2–27.5), 7.3 months (4.9–11.1), and 5.1 months (4.0–9.0) in 1 BM, 2–4 BM, and 5–10 BM, respectively. Compared to 2–4 BM, 1 BM had significantly better OS (hazard ratio [HR] 0.59, 95% CI 0.40–0.87; p = 0.0075); however, 5–10 BM had comparable OS (HR 1.36, 95% CI 0.85–2.19; p = 0.199). There was no significant difference in LC, DIF, and RN between tumor number groups, but DIF was lower in 1 BM. RN of grade 2 or higher occurred in 21 patients (13.5%); grade 4 and 5 RN were not observed. Conclusions: The linac-based fSRT and SRS for patients with 5–10 BMs is comparable to that for patients with 2–4 BMs in OS, LC, DIF, and RN. It seems reasonable to use linac-based fSRT and SRS in patients with 5–10 BMs.
- 28 December 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-10
Open AccessFeasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
Background: Linac-based fractionated stereotactic radiotherapy (fSRT) and stereotactic radiosurgery (SRS) are increasingly being used to manage patients with multiple metastases. This retrospective cohort study aimed to compare the outcomes after linac-based fSRT and SRS between three patient groups classified based on the number of brain metastases (BMs): 1 BM, 2–4 BM, 5–10 BM. Methods: The data of consecutive patients with 1–10 BMs treated with fSRT or SRS between July 2016 and June 2018 at a single institution were collected. Patients with previous whole-brain radiotherapy (WBRT), concurrent use of WBRT, or surgical resection were excluded from the analysis. A total of 176 patients were classified into three groups according to the number of BMs: 78, 67, and 31 patients in 1 BM, 2–4 BM, and 5–10 BM, respectively. The Kaplan–Meier method was used to estimate overall survival (OS) curves, and the cumulative incidence with competing risks was used to estimate local control (LC), distant intracranial failure (DIF), and radiation necrosis (RN). Results: Median OS was 19.8 months (95% confidence interval [CI] 10.2–27.5), 7.3 months (4.9–11.1), and 5.1 months (4.0–9.0) in 1 BM, 2–4 BM, and 5–10 BM, respectively. Compared to 2–4 BM, 1 BM had significantly better OS (hazard ratio [HR] 0.59, 95% CI 0.40–0.87; p = 0.0075); however, 5–10 BM had comparable OS (HR 1.36, 95% CI 0.85–2.19; p = 0.199). There was no significant difference in LC, DIF, and RN between tumor number groups, but DIF was lower in 1 BM. RN of grade 2 or higher occurred in 21 patients (13.5%); grade 4 and 5 RN were not observed. Conclusions: The linac-based fSRT and SRS for patients with 5–10 BMs is comparable to that for patients with 2–4 BMs in OS, LC, DIF, and RN. It seems reasonable to use linac-based fSRT and SRS in patients with 5–10 BMs.